- /
- Supported exchanges
- / US
- / TECX.NASDAQ
Tectonic Therapeutic, Inc. (TECX NASDAQ) stock market data APIs
Tectonic Therapeutic, Inc. Financial Data Overview
Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein-coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin. It is also developing TX2100 for the treatment of hereditary hemorrhagic telangiectasia; GPCR modulator bispecific for treating fibrosis; and other GPCR modulators. The company is headquartered in Watertown, Massachusetts.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Tectonic Therapeutic, Inc. (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Tectonic Therapeutic, Inc. data using free add-ons & libraries
Get Tectonic Therapeutic, Inc. Fundamental Data
Tectonic Therapeutic, Inc. Fundamental data includes:
- Net Revenue:
- EBITDA: -74 961 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-09-30
- EPS/Forecast: -1.0471
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Tectonic Therapeutic, Inc. News
New
Tectonic Therapeutic Surges 12% On Positive Phase 1b Topline Data For TX45
(RTTNews) - Tectonic Therapeutic, Inc. (TECX) jumped 12.33% to $20.92, gaining $2.30, after announcing positive topline results from its Phase 1b Part B clinical trial of TX45 in patients with Group 2...
Tectonic surges on phase 1b data for pulmonary hypertension asset
[Percentage Symbol with Slash Transforming into Upward Growth Graph Representing Financial Gains and Market Trends] J Studios * Tectonic Therapeutic (TECT) has skyrocketed ~29% in after-hours tradi...
Tectonic Therapeutic Announces Positive Topline Data from Phase 1b Part B Clinical Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFrEF
TX45 improved both left heart function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with reduced Ejection Fraction (“PH‑HFrEF”)TX45 was well tolera...
Tectonic Therapeutic a new outperform at Oppenheimer on heart drug asset
[Sign for Wall Street in New York City] Pharrel Wiliams * Oppenheimer has initiated coverage of Tectonic Therapeutic (NASDAQ:TECX [https://seekingalpha.com/symbol/TECX]) with an outperform rating c...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.